Zobrazeno 1 - 10
of 7 298
pro vyhledávání: '"car-t cells"'
Autor:
Haiqiong Zheng, Houli Zhao, Shi Han, Delin Kong, Qiqi Zhang, Mingming Zhang, Yijin Chen, Meng Zhang, Yongxian Hu, He Huang
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2024)
Abstract Relapsed/refractory T cell-derived malignancies present with high heterogeneity and poor prognoses. Recently, chimeric antigen receptor (CAR)-T cell therapy has shown remarkable safety and efficacy in the treatment of B cell-derived malignan
Externí odkaz:
https://doaj.org/article/abc8c408c696440888885f5a945c4e91
Autor:
Blanca Ferrer-Lores, Alfonso Ortiz-Algarra, Alfonso Picó-Peris, Alejandra Estepa-Fernández, Fuensanta Bellvís-Bataller, Glen J. Weiss, Almudena Fuster-Matanzo, Juan Pedro Fernández, Ana Jimenez-Pastor, Rafael Hernani, Ana Saus-Carreres, Ana Benzaquen, Laura Ventura, José Luis Piñana, Ana Belén Teruel, Alicia Serrano-Alcalá, Rosa Dosdá, Pablo Sopena-Novales, Aitana Balaguer-Rosello, Manuel Guerreiro, Jaime Sanz, Luis Martí-Bonmatí, María José Terol, Ángel Alberich-Bayarri
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Background This multicentre retrospective observational study aims to develop imaging-based prognostic and predictive models for relapsed/refractory (R/R) B-cell lymphoma patients undergoing CAR-T therapy by integrating clinical data and ima
Externí odkaz:
https://doaj.org/article/0057ba293b9c45989ef0c7a2fb4073b2
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-30 (2024)
Abstract Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both ge
Externí odkaz:
https://doaj.org/article/bedbc000af50411f9315fd5d66600049
Autor:
Tongpeng Xu, Tian Tian, Chen Wang, Xiaofeng Chen, Xiangrong Zuo, Hanyu Zhou, Jianan Bai, Chenhui Zhao, Sujie Fu, Chongqi Sun, Ting Wang, Ling Zhu, Jingzhi Zhang, Enxiu Wang, Ming Sun, Yongqian Shu
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Despite remarkable achievements in applying chimeric antigen receptor (CAR)-T cells to treat hematological malignancies, they remain much less effective against solid tumors, facing several challenges affecting their clinical use.
Externí odkaz:
https://doaj.org/article/6b50711b262f4cfdbe647fef7b8bbc12
Autor:
Nastaran Khazamipour, Htoo Zarni Oo, Nader Al-Nakouzi, Mona Marzban, Nasrin Khazamipour, Morgan E Roberts, Negin Farivar, Igor Moskalev, Joey Lo, Fariba Ghaidi, Irina Nelepcu, Alireza Moeen, Sarah Truong, Robert Dagil, Swati Choudhary, Tobias Gustavsson, Beibei Zhai, Sabine Heitzender, Ali Salanti, Poul H Sorensen, Mads Daugaard
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 11, Pp 2775-2794 (2024)
Abstract Glycosaminoglycans are often deprioritized as targets for synthetic immunotherapy due to the complexity of glyco-epitopes and limited options for obtaining specific subtype binding. Solid tumors express proteoglycans that are modified with o
Externí odkaz:
https://doaj.org/article/d3295f9f532345a98191aa5661d49d04
Publikováno v:
Onco, Vol 4, Iss 3, Pp 232-240 (2024)
The use of chimeric antigen receptors (CAR T-cells) for the treatment of patients with malignant haematological diseases has become a well-established application for conditions such as refractory or relapsed B-cell acute lymphoblastic leukaemia (B-A
Externí odkaz:
https://doaj.org/article/681b84c48d244b28a1b50f50a66d3c15
Autor:
Angela C. Court, Eliseo Parra-Crisóstomo, Pablo Castro-Córdova, Luiza Abdo, Emmanuel Arthur Albuquerque Aragão, Rocío Lorca, Fernando E. Figueroa, Martín Hernán Bonamino, Maroun Khoury
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Apoptosis, a form of programmed cell death, is critical for the development and homeostasis of the immune system. Chimeric antigen receptor T (CAR-T) cell therapy, approved for hematologic cancers, retains several limitations and
Externí odkaz:
https://doaj.org/article/d0d64939ef1b4ab188402484e84e7de2
Autor:
Shafieeh Mansoori, Ahmad Noei, Amirhosein Maali, Seyedeh Sheila Seyed-Motahari, Zahra Sharifzadeh
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-22 (2024)
Abstract CAR-T cell therapy is known as an effective therapy in patients with hematological malignancies. Since 2017, several autologous CAR-T cell (auto-CAR-T) drugs have been approved by the US Food and Drug Administration (FDA) for the treatment o
Externí odkaz:
https://doaj.org/article/8699bf73261d447d9122bc152fd6efde
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 13, Pp 413-433 (2024)
Shivani Srivastava,1,* Anuradha Tyagi,2,* Vishakha Anand Pawar,3,* Nawaid Hussain Khan,4,* Kavita Arora,5,6 Chaitenya Verma,7,8 Vinay Kumar9 1Department of Pathology, School of Medicine, Yale University, New Haven, CT, USA; 2Departmen
Externí odkaz:
https://doaj.org/article/44a7f49d7e9943b9bdb744d4022ae00a
Autor:
Qiusui Mai, Bailin He, Shikai Deng, Qing Zeng, Yanwen Xu, Cong Wang, Yunyi Pang, Sheng Zhang, Jinfeng Li, Jinfeng Zeng, Liqin Huang, Yongshui Fu, Chengyao Li, Tingting Li, Xiaojun Xu, Ling Zhang
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Epstein-Barr virus (EBV) related post-transplant lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), for which no standard ther
Externí odkaz:
https://doaj.org/article/4f77cc45aa3f49358bfb6eacd3798041